1. Home
  2. SSP vs IKT Comparison

SSP vs IKT Comparison

Compare SSP & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$2.75

Market Cap

264.6M

Sector

Industrials

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
IKT
Founded
1878
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.6M
220.5M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
SSP
IKT
Price
$2.75
$1.82
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.95
$5.00
AVG Volume (30 Days)
574.7K
541.3K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
$2,150,585,000.00
N/A
Revenue This Year
$8.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$1.33
52 Week High
$5.39
$2.26

Technical Indicators

Market Signals
Indicator
SSP
IKT
Relative Strength Index (RSI) 29.81 58.93
Support Level $2.73 $1.63
Resistance Level $3.01 $1.91
Average True Range (ATR) 0.21 0.07
MACD -0.04 0.01
Stochastic Oscillator 21.37 95.12

Price Performance

Historical Comparison
SSP
IKT

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: